Unknown PHASE1 INTERVENTIONAL 2-arm NCT03282435

Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

Treatment of Non-small Cell Lung Cancer With CIK Cells Blocked by PD-1 Antibody

Sponsor: Dalian University

Interventions CIK cells with PD-1 blocking CIK cells without PD-1 blocking standard lung cancer treament

Updated 5 times since 2017 Last updated: Sep 12, 2017 Started: Jan 31, 2018 Primary completion: Jan 31, 2023 Completion: Jan 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Non-small Cell Lung Cancer and is currently ongoing. Dalian University leads this study, which shows 5 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Feb 2023 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Feb 2023 [monthly]

Not Yet Recruiting PHASE1
Oct 2017 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dalian University

Data source: Dalian University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.